Plus Therapeutics has received FDA approval to start the ReSPECT-LM dose optimization trial for its drug, REYOBIQ™, aimed at treating leptomeningeal metastases. The trial’s primary goal is to establish the optimal dosing schedule for a future registrational trial. This new study builds on the recommended Phase 2 dose identified in a completed Phase 1 trial. The initiative benefits from a $17.6 million award, which will support the trial’s execution. This development marks a significant step in advancing treatment options for patients with this challenging condition, potentially improving outcomes and expanding therapeutic possibilities.
Plus Therapeutics Gains FDA Approval for Key Dose Optimization Trial
7 responses to “Plus Therapeutics Gains FDA Approval for Key Dose Optimization Trial”
-
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
-
Nnbet4, here I come! Always up for a bit of a flutter. I’ll let you know if it’s a good one! nnbet4
-
Looking for a site with a massive game collection? Afunjogo has it all! Slots, live casino, sports… tons of options! Check out afunjogo
-
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me? https://www.binance.info/sl/register?ref=GQ1JXNRE
-
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article. https://www.binance.com/register?ref=IXBIAFVY
-
Qibetvn caught my eye the other day. The site looks pretty clean, and the mobile experience is decent. Still testing the waters, but so far, so good. Definitely worth a peep: qibetvn
-
Your article helped me a lot, is there any more related content? Thanks! https://www.binance.info/bn/register?ref=WTOZ531Y
Leave a Reply